Showing 1-10 of about 162 articles.

Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights

WEST CONSHOHOCKEN, Pa., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its fourth quarter and full year 2020 financial results and highlights. “We...

February 25, 2021

The Rosen Law Firm PA

ICPT FINAL DEADLINE MONDAY: ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Intercept Pharmaceuticals, Inc. Investors of Important January 4 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm – ICPT

NEW YORK, Jan. 01, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between...

January 01, 2021

Renown Health

RENOWN INSTITUTE FOR HEALTH INNOVATION EXPANDS PARTNERSHIP WITH GILEAD SCIENCES AND SIEMENS HEALTHINEERS TO OFFER ELF- ENHANCED LIVER FIBROSIS TESTING FOR NEVADA NASH STUDY PARTICIPANTS

RENO, Nev., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Renown Institute for Health Innovation (IHI) announced today that the organization and Gilead Sciences, Inc. will be joining forces with Siemens...

December 15, 2020

Galectin Therapeutics Inc.

Galectin Therapeutics, Inc. to Present at the 4th Annual Digital NASH Summit on December 17, 2020

NORCROSS, Ga., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Pol F. Boudes,...

December 11, 2020

The Rosen Law Firm PA

ROSEN, A GLOBAL AND LEADING LAW FIRM, Reminds Intercept Pharmaceuticals, Inc. Investors of Important Deadline in Securities Class Action – ICPT

NEW YORK, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between...

December 10, 2020

The Rosen Law Firm PA

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Reminds Intercept Pharmaceuticals, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – ICPT

NEW YORK, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between...

December 03, 2020

Galectin Therapeutics Inc.

Galectin Therapeutics to Webcast Corporate Update on December 3, 2020 after Annual Meeting of Stockholders

NORCROSS, Ga., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that management will...

December 01, 2020

Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting November 13, 2020, Including NASH Expert Insights on the Ongoing Open Label Arm of Resmetirom 52-Week Phase 3 MAESTRO-NAFLD-1 Trial

Dr. Stephen Harrison will present Resmetirom for the Treatment of NASH: Early Data from the Phase 3 MAESTRO Clinical Trials | The Liver Meeting Digital Experience™, AASLD Product Theater on Friday,...

November 13, 2020

Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights

CONSHOHOCKEN, Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it completed enrollment in its MAESTRO NAFLD-1 clinical trial of resmetirom in...

November 05, 2020

Sonic Incytes Medical Corp.

Sonic Incytes Announces FDA Clearance and US Launch of Velacur™ to Help Manage Emerging Health Crisis

VANCOUVER, British Columbia, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Sonic Incytes Medical Corporation is pleased to announce the US commercial release of VelacurTM, the world’s first handheld 3D liver...

October 20, 2020

Showing 1-10 of about 162 articles.

Search Results

Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights

ICPT FINAL DEADLINE MONDAY: ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Intercept Pharmaceuticals, Inc. Investors of Important January 4 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm – ICPT

RENOWN INSTITUTE FOR HEALTH INNOVATION EXPANDS PARTNERSHIP WITH GILEAD SCIENCES AND SIEMENS HEALTHINEERS TO OFFER ELF- ENHANCED LIVER FIBROSIS TESTING FOR NEVADA NASH STUDY PARTICIPANTS

Galectin Therapeutics, Inc. to Present at the 4th Annual Digital NASH Summit on December 17, 2020

ROSEN, A GLOBAL AND LEADING LAW FIRM, Reminds Intercept Pharmaceuticals, Inc. Investors of Important Deadline in Securities Class Action – ICPT

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Reminds Intercept Pharmaceuticals, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – ICPT

Galectin Therapeutics to Webcast Corporate Update on December 3, 2020 after Annual Meeting of Stockholders

Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting November 13, 2020, Including NASH Expert Insights on the Ongoing Open Label Arm of Resmetirom 52-Week Phase 3 MAESTRO-NAFLD-1 Trial

Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights

Sonic Incytes Announces FDA Clearance and US Launch of Velacur™ to Help Manage Emerging Health Crisis

Newswire Distribution Network & Management

About Us